Small Pharma Inc. (DMTTF:OTCQB) plans to continue advancing two drug candidates for major depressive disorder this year, leading to possible stock catalysts, reported ROTH Capital Partners analyst Elmer Piros in a May 25th research note.
Also of note, the potential return for investors of Small Pharma is in multi-bagger territory, given the current share price is around CA$0.15 and ROTH's target price on it is more than 30 times that, at CA$5. ROTH's recommendation on the company is Buy.
The England-based firm's drugs, SPL026 and SPL028, are proprietary versions of the psychedelic, DMT, or N, N-dimethyltryptamine.
Small Pharma's management, in its recent clinical update, reiterated that the more advanced of the two, SPL026 (injectable DMT fumarate), is currently being evaluated in combination with talk therapy, in an in-progress Phase 2 trial in the United Kingdom, Piros noted. Results of this study now are expected in H2/22, pushed back from H1/22 because of enrollment delays due to COVID-19.
Significantly, Small Pharma added two trials to its SPL026 development program, which it plans to launch this year.
One, a drug interaction study, will evaluate the impact of antidepressants used in conjunction with SPL026 in major depressive disorder. In the study, patients taking selective serotonin reuptake inhibitors (SSRIs) without success will be compared to patients not taking them. If patients on SSRIs could successfully supplement their depression therapy with SPL026, this would expand the patient base and market for Small Pharma's drug.
Encouragingly, "a recent study with psilocybin combined with SSRIs did not result in adverse effects in healthy volunteers," Piros relayed.
The second SPL026 study will be another Phase 1, to be done using healthy volunteers, in which intramuscular versus intravenous SPL026 formulations and administration will be assessed. Intramuscular administration would afford patients easier access to and more convenient delivery of SPL026.
Regarding SPL028 (injectable deuterated DMT), it is on the verge of moving from the preclinical into the clinical phase, wrote Piros. In H2/22, Small Pharma intends to launch a Phase 1 trial of SPL028, also in major depressive disorder, using intramuscular and intravenous formulations.
With SPL028, the company aims to deliver a longer psychedelic experience than that experienced with SPL026. If achieved, SPL028 might be used to help treat other mental health ailments.
"In vitro data indicate that with SPL028, there was a reduction of clearance and a significant extension of half-life (when compared to SPL026), indicating a potentially longer duration (greater than 30 minutes) in upcoming human clinical trials," added Piros.
|Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter.||Subscribe|
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees, or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in the securities mentioned. Directors, officers, employees, or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees, and contributors to Streetwise Reports are not licensed, medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures for Roth Capital Partners, Small Pharma Inc., May 25, 2022
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH.